Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 127

Sort by

Sort Order Select

Journal Articles

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E -mutated multiple myeloma

Blood (2023) 141 (14): 1685–1690.

https://doi.org/10.1182/blood.2022017789

Published: 2023

Includes: Supplemental data

Journal Articles

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1 -Mutated Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2010–2013.

https://doi.org/10.1182/blood-2022-166084

Published: 2022

Journal Articles

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Blood (2022) 140 (Supplement 1): 1836–1838.

https://doi.org/10.1182/blood-2022-156309

Published: 2022

Journal Articles

Risk Factors Influencing Humoral Response to COVID 19 Vaccination after Allogeneic Stem Cell Transplantation

Marie Luise Hütter-Krönke, Adela Neagoie, Igor Wolfgang Blau, Lam Giang Vuong, Maral Saadati, Axel Benner, Lars Bullinger, Hartmut Döhner, Donald Bunjes, Elisa Sala

Blood (2022) 140 (Supplement 1): 4755–4756.

https://doi.org/10.1182/blood-2022-170006

Published: 2022

Journal Articles

Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma

Elias K Mai, Stefanie Huhn, Kaya Miah, Alexandra M Poos, Christof Scheid, Katja Weisel, Uta Bertsch, Markus Munder, Oscar Berlanga, Dirk Hose, Anja Seckinger, Anna Jauch, Igor Wolfgang Blau, Mathias Haenel, Hans Salwender, Axel Benner, Marc S Raab, Hartmut Goldschmidt, Niels Weinhold

Blood (2022) 140 (Supplement 1): 2341–2343.

https://doi.org/10.1182/blood-2022-156169

Published: 2022

Journal Articles

Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 3315–3316.

https://doi.org/10.1182/blood-2022-163430

Published: 2022

Journal Articles

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Blood (2022) 140 (Supplement 1): 6053–6055.

https://doi.org/10.1182/blood-2022-165088

Published: 2022

Journal Articles

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Blood (2022) 140 (Supplement 1): 551–554.

https://doi.org/10.1182/blood-2022-167480

Published: 2022

Journal Articles

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Blood (2022) 140 (Supplement 1): 739–742.

https://doi.org/10.1182/blood-2022-167138

Published: 2022

Journal Articles

Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications

Blood (2021) 138 (Supplement 1): 692.

https://doi.org/10.1182/blood-2021-147256

Published: 2021

Journal Articles

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Tommaso Matteuzzi, Daniele Dall'Olio, Eric Sträng, Alessandra Merlotti, Javier Martinez Elicegui, Axel Benner, Maral Saadati, Julia Krzykalla, Caroline A. Heckman, Ana Heredia Casanoves, Jurjen Versluis, María Abáigar, Alberto Hernandez-Sanchez, Laura Jamilis, Peter JM Valk, Klaus H. Metzeler, Rosa Ayala, Joaquin Martinez Lopez, Herve Dombret, Pau Montesinos, Jorge Sierra, Claude Preudomme, Frederick Damm, Ken I Mills, Raúl Azibeiro Melchor, Jiří Mayer, Christian Thiede, Maria Teresa Voso, Sergio Amadori, Guillermo Sanz, Frederico Calado, Konstanze Döhner, Verena I Gaidzik, Michael Heuser, Torsten Haferlach, Marta Sobas, Amin T. Turki, Dirk Reinhardt, Rubén Villoria Medina, Michel van Speybroeck, Renate Schulze-Rath, Jesús M Hernández Rivas, Brian J.P Huntly, Hartmut Döhner, Gert J. Ossenkoppele, Castellani Gastone, Lars Bullinger

Blood (2021) 138 (Supplement 1): 3438.

https://doi.org/10.1182/blood-2021-152215

Published: 2021

Journal Articles

Two-Year Evaluation of the German Clinical Amyloidosis Registry

Ute Hegenbart, Niklas Fuhr, Laura Huber, Christoph Kimmich, Kaya Veelken, Tobias Dittrich, Rita Ziehl, Fabian aus dem Siepen, Alexander Carpinteiro, Timon Hansen, Carsten Müller-Tidow, Axel Benner, Stefan Schönland

Blood (2021) 138 (Supplement 1): 3780.

https://doi.org/10.1182/blood-2021-152713

Published: 2021

Journal Articles

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

Blood (2021) 138 (Supplement 1): 608.

https://doi.org/10.1182/blood-2021-150766

Published: 2021

Journal Articles

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 4041.

https://doi.org/10.1182/blood-2021-149521

Published: 2021

Journal Articles

Easix before Conditioning Therapy Predicts Sepsis after Allogeneic Stem Cell Transplantation

Felix Korell, Nicholas Schreck, Axel Benner, Tobias Liebregts, Stefan Schönland, Ute Hegenbart, Aleksandar Radujkovic, Michael Schmitt, Peter Dreger, Thomas Luft

Blood (2021) 138 (Supplement 1): 1774.

https://doi.org/10.1182/blood-2021-153104

Published: 2021

Journal Articles

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1 -mutated AML: results from the AMLSG 09-09 trial

Blood (2020) 136 (26): 3041–3050.

https://doi.org/10.1182/blood.2020005998

Published: 2020

Includes: Supplemental data

Journal Articles

Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial

Marc S. Raab, MD, Nicola Giesen, MD, Christof Scheid, MD, Britta Besemer, Kaya Miah, Axel Benner, Ivana Metzler, MD, Cyrus Khandanpour, PD, MD, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, MD, Gunhild Mechtersheimer, Benjamin Goeppert, Albrecht Stenzinger, Hartmut Goldschmidt, MD, Katja Weisel, MD, Manik Chatterjee

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-142600

Published: 2020

Journal Articles

Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma

Lukas John, Kaya Miah, Axel Benner, Elias K Mai, MD, Katharina Kriegsmann, MD, Michael Hundemer, MD, Carsten Mueller-Tidow, MD, Karin Jordan, MD, Hartmut Goldschmidt, MD, Marc S. Raab, MD, Nicola Giesen, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-136686

Published: 2020

Journal Articles

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-141552

Published: 2020

Journal Articles

Higher Dose of CPX-351 Is Associated with Prolonged Hematologic Recovery: Results from an Interim Safety Analysis of the Randomized, Phase III AMLSG 30-18 Trial

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-138738

Published: 2020

NARROW

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E -mutated multiple myeloma

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1 -Mutated Acute Myeloid Leukemia

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Risk Factors Influencing Humoral Response to COVID 19 Vaccination after Allogeneic Stem Cell Transplantation

Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma

Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Two-Year Evaluation of the German Clinical Amyloidosis Registry

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Easix before Conditioning Therapy Predicts Sepsis after Allogeneic Stem Cell Transplantation

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1 -mutated AML: results from the AMLSG 09-09 trial

Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial

Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Higher Dose of CPX-351 Is Associated with Prolonged Hematologic Recovery: Results from an Interim Safety Analysis of the Randomized, Phase III AMLSG 30-18 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only